A Study in Healthy People to Test Whether BI 3000202 Affects How 2 Other Medicines (Rosuvastatin and Digoxin) Are Taken up in the Body

Sponsor
Boehringer Ingelheim
Study ID
NCT07215260
Phase
PHASE1
Status
Completed

Conditions

  • Healthy

Eligibility Criteria

Sex
ALL
Age
18 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • BI 3000202 — DRUG
    BI 3000202
  • Rosuvastatin — DRUG
    Rosuvastatin
  • Digoxin — DRUG
    Digoxin

Study Details

The objective of this trial is to assess the effect of BI 3000202 on the pharmacokinetics of rosuvastatin and digoxin given as a cocktail.

Key Dates

Start date
Nov 5, 2025
Status verified
Dec 2025
Primary completion
Dec 7, 2025
Completion
Dec 18, 2025

Study Design

Enrollment
14 participants (actual)
Allocation
NA
Intervention model
CROSSOVER
Primary purpose
TREATMENT

Arms

  • Experimental: Cocktail (Reference) then BI 3000202-Cocktail (Test)
    Cocktail consisting of rosuvastatin and digoxin.

Primary Outcome Measure

Area under the concentration-time curve of rosuvastatin in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) [ Time Frame: Up to Day 7 ]

Related Studies